Literature DB >> 23764082

mTOR signaling pathway in penile squamous cell carcinoma: pmTOR and peIF4E over expression correlate with aggressive tumor behavior.

Carla Ferrandiz-Pulido1, Emili Masferrer, Agustin Toll, Javier Hernandez-Losa, Sergio Mojal, Ramon M Pujol, Santiago Ramon y Cajal, Ines de Torres, Vicente Garcia-Patos.   

Abstract

PURPOSE: Penile squamous cell carcinoma is a rare neoplasm associated with a high risk of metastasis and morbidity. There are limited data on the role of the mTOR signaling pathway in penile squamous cell carcinoma carcinogenesis and tumor maintenance. We assessed a possible role for mTOR signaling pathway activation as a potential predictive biomarker of outcome and a therapeutic target for penile cancer.
MATERIAL AND METHODS: A cohort of 67 patients diagnosed with invasive penile squamous cell carcinoma from 1987 to 2010 who had known HPV status were selected for study. Tissue microarrays were constructed with 67 primary penile squamous cell carcinomas, matched normal tissues and 8 lymph node metastases. Immunohistochemical staining was performed for p53, pmTOR, pERK, p4E-BP1, eIF4E and peIF4E. Expression was evaluated using a semiquantitative H-score on a scale of 0 to 300.
RESULTS: Expression of pmTOR, p4E-BP1, eIF4E and peIF4E was increased in penile tumors compared with matched adjacent normal tissues, indicating activation of the mTOR signaling pathway in penile tumorigenesis. Over expression of pmTOR, peIF4E and p53 was significantly associated with lymph node disease. peIF4E and p53 also correlated with a poor outcome, including recurrence, metastasis or disease specific death. In contrast, pERK and p4E-BP1 were associated with lower pT stages. pmTOR and intense p53 expression was associated with HPV negative tumors.
CONCLUSIONS: Activation of mTOR signaling may contribute to penile squamous cell carcinoma progression and aggressive behavior. Targeting mTOR or its downstream signaling targets, such as peIF4E, may be a valid therapeutic strategy.
Copyright © 2013 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  4E-BP1; ERK; HPV; MAPK; MAPK-interacting protein kinase; MNK; PI3K; SCC; TMA; TP53; biological markers; carcinoma; eIF4E; eukaryotic translation initiation factor 4E; eukaryotic translation initiation factor 4E-binding protein 1; extracellular regulated kinase; high risk HPV; hrHPV; human; human papillomavirus; immunohistochemistry; mTOR; mTOR protein; mammalian target of rapamycin; mitogen activated protein kinase; p; penis; phosphatidylinositol 3-kinase; phosphorylated; squamous cell; squamous cell carcinoma; tissue microarray; tumor protein 53 gene

Mesh:

Substances:

Year:  2013        PMID: 23764082     DOI: 10.1016/j.juro.2013.06.015

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  22 in total

1.  Upregulation of nucleus HDGF predicts poor prognostic outcome in patients with penile squamous cell carcinoma bypass VEGF-A and Ki-67.

Authors:  Dawei Li; Zhen Han; Jikai Liu; Xiang Zhang; Juchao Ren; Lei Yan; Hainan Liu; Zhonghua Xu
Journal:  Med Oncol       Date:  2013-09-03       Impact factor: 3.064

2.  Strong association of insulin-like growth factor 1 receptor expression with histologic grade, subtype, and HPV status in penile squamous cell carcinomas: a tissue microarray study of 112 cases.

Authors:  Sheila F Faraj; Nilda Gonzalez-Roibon; Enrico Munari; Rajni Sharma; Arthur L Burnett; Antonio L Cubilla; George J Netto; Alcides Chaux
Journal:  Virchows Arch       Date:  2017-03-27       Impact factor: 4.064

3.  HPV-negative penile squamous cell carcinoma: disruptive mutations in the TP53 gene are common.

Authors:  Karl Kashofer; Elke Winter; Iris Halbwedl; Andrea Thueringer; Marisa Kreiner; Stefan Sauer; Sigrid Regauer
Journal:  Mod Pathol       Date:  2017-04-07       Impact factor: 7.842

4.  Immunohistochemical expression of ARID1A in penile squamous cell carcinomas: a tissue microarray study of 112 cases.

Authors:  Sheila F Faraj; Alcides Chaux; Nilda Gonzalez-Roibon; Enrico Munari; Antonio L Cubilla; Ie-Ming Shih; George J Netto
Journal:  Hum Pathol       Date:  2015-02-12       Impact factor: 3.466

Review 5.  [Conventional grading vs. molecular grading : Decision aids for clinical routine].

Authors:  C Kakies; D Louise Dräger; P Spiess; O W Hakenberg; C Protzel
Journal:  Urologe A       Date:  2021-06-28       Impact factor: 0.639

6.  Inhibition of Mitogen-activated Protein Kinase (MAPK)-interacting Kinase (MNK) Preferentially Affects Translation of mRNAs Containing Both a 5'-Terminal Cap and Hairpin.

Authors:  Nadejda L Korneeva; Anren Song; Hermann Gram; Mary Ann Edens; Robert E Rhoads
Journal:  J Biol Chem       Date:  2015-12-14       Impact factor: 5.157

7.  Penile cancer: potential target for immunotherapy?

Authors:  Joren Vanthoor; Gigi Vos; Maarten Albersen
Journal:  World J Urol       Date:  2020-11-03       Impact factor: 4.226

8.  Impact of PI3K-AKT-mTOR Signaling Pathway Up-regulation on Prognosis of Penile Squamous-Cell Carcinoma: Results From a Tissue Microarray Study and Review of the Literature.

Authors:  Mounsif Azizi; Dominic H Tang; Daniel Verduzco; Charles C Peyton; Juan Chipollini; Zhigang Yuan; Braydon J Schaible; Jun-Min Zhou; Peter A Johnstone; Anna Giuliano; Jasreman Dhillon; Philippe E Spiess
Journal:  Clin Genitourin Cancer       Date:  2018-09-22       Impact factor: 3.121

9.  Clinical significance of aberrant mammalian target of rapamycin expression in stage IIIB colon cancer.

Authors:  Meiling Wen; Baoxiu Li; Xiaofei Cao; Chengyin Weng; Yong Wu; Xisheng Fang; Xiaoshi Zhang; Guolong Liu
Journal:  Oncol Lett       Date:  2014-06-25       Impact factor: 2.967

10.  Phosphorylated Mnk1 and eIF4E are associated with lymph node metastasis and poor prognosis of nasopharyngeal carcinoma.

Authors:  Jun Zheng; Jiao Li; Lina Xu; Guiyuan Xie; Qiuyuan Wen; Jiadi Luo; Duo Li; Donghai Huang; Songqing Fan
Journal:  PLoS One       Date:  2014-02-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.